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Abstract. We undertook a sequential study in 29 chil-
dren with steroid-sensitive nephrotic syndrome (SSNS)
off treatment to seek evidence for T-cell activation in
relapse. T-cell subsets and activation markers were
analysed using two-colour flow cytometry. Soluble IL2
receptor (sIL2R) was measured in serum and urine by
enzyme-linked immunosorbent assay (ELISA). Fifteen
children were examined in remission and subsequent
relapse (group A) and fourteen remained in remission
(group B). In group A the proportion of CD4+ cells
expressing the activation marker CD25 (alpha-chain
of the IL2 receptor) increased significantly from remis-
sion to relapse: CD4+25+ cells rose from 5.6 to 7.0%
of total lymphocytes, and from 15.8 to 19.1% of CD4+
lymphocytes (paired t test: P< 0.0005 and < 0.001
respectively). No correlations were found between
CD4+25+ cells and plasma albumin or cholesterol
concentrations. SIL2R concentration in serum did not
change in relapse, but increased significantly in urine
from 272 to 592 U/mg creatinine (P<0.01). No signi-
ficant difference was found in remission between groups
A and B. We conclude that early relapse in SSNS is
associated with activation of CD4+ (T-helper) cells
which is not secondary due to the nephrotic state itself.
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Introduction
Steroid-sensitive nephrotic syndrome and minimal-
change nephrotic syndrome (MCNS) in childhood
have been associated with several in-vivo and in-vitro
abnormalities of T lymphocytes [1], including
decreased delayed hypersensitivity [2] and reduced
responsiveness of lymphocytes to mitogens [2,3].
Relapse may be triggered by a viral upper respiratory
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tract infection or an allergic event, whereas measles
infection, which is known to inhibit T-cell function
[4], is associated with remission [5]. The clinical
response of SSNS to immunosuppressive treatment is
also further evidence for an immune pathogenesis.
Monoclonal antibodies have been used to identify
T-cell activation and T-cell subsets in peripheral blood
in relapse in SSNS, but with inconclusive results so
far. Some authors found no changes (compared to
patients in remission or normal controls) in
CD2+/CD3+ (total T cells), CD4+ (T-helper cells)
and CD8+ (cytotoxic/suppressor T cells) subsets [6,7],
whereas others reported a decrease in CD3 + and CD4+
cells [8]. CD25 (or Tac) is the a-chain of the IL2
receptor; it is expressed on activated T cells and associ-
ates with the beta and gamma chain to form the high
affinity IL2 receptor [9]. CD25 showed a slight propor-
tional increase in CD3 [10], but was unchanged in
two other studies [7,8]. Expression of DR (MHCII)
has been reported to be increased in CD8+ cells [8]
and decreased in CD3+ and CD4+ cells [10]. Subsets
of patients in remission off treatment did not differ
significantly from controls [6,8]. Increased expression
of CD25 has also been found on cultured and stimu-
lated lymphocytes [11]. Elevated soluble IL2 receptor
(sIL2R) has been recorded in various conditions associ-
ated with immune activation [12]. In SSNS increased
levels have been shown in serum and urine [13,14].
However, these studies in SSNS differed in design:
some included patients both on and off treatment and
only two studies examined changes sequentially in
relapse and remission [10,13], the former showing
increased CD3+25+ and CD4+L-selectin+ cells in
relapse. A previous preliminary study from our unit,
analysing different patients in different stages of SSNS,
on and off treatment, had shown a slight increase in
CD4+25+ lymphocytes and serum sIL2R in
relapse [15]. Lymphocyte subsets vary considerably
between individuals and are age-related [16].
Immunosuppressive treatment also affects the expres-
sion of the surface markers and the composition of
lymphocyte subsets [17,18].
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We therefore designed a prospective trial to follow
individual patients with SSNS off treatment sequen-
tially in remission and in early relapse. The primary
hypothesis to be tested was that CD4+ cells were
activated in relapse, compared to remission, expressing
CD25. Secondly we analysed other lymphocyte activa-
tion markers and subsets.
Subjects and methods
Patients. SSNS was defined according to the International
Study for Kidney Disease in Childhood [19]. Children with
a stable remission (>6 months) were considered for entry
into the study. They were on maintenance treatment (cyclo-
sporin A, levamisole or alternate-day steroids), which was
due to be stopped to assess the tendency to relapse. Criteria
for admission were: (I) normal plasma creatinine,
(2) minimal-change histology (MCNS) if biopsy had been
performed, (3) off cyclosporin A, levamisole and steroids for
>2 weeks, (4) off cyclophosphamide for >6 months, and
(5) no overt infection at time of investigation. Between
November 1992 and January 1994, 260 patients with SSNS
attended the Nephrotic Clinic. From this group, 29 children
were eligible for the study. None of this group had been
included in the previous study [15]. Informed consent was
obtained. The patients were seen at intervals of 1-2 weeks,
on five occasions, unless they relapsed earlier. If a relapse
occurred (2 days^2+ proteinuria on dipstick testing and
urine albumin/creatinine ratio >1.0mg/mg; normal <0.1),
the child was investigated within the next 48 h (i.e. on day 3
or 4 after onset of proteinuria) to disentangle primary effects
from possibly secondary effects related to the nephrotic state
itself. Subsequently, standard relapse treatment with predni-
solone was commenced. The study protocol was approved
by the Ethical Committee of our hospital.
Surface phenotyping of peripheral blood lymphocytes using
monoclonal antibodies. Peripheral blood was collected in the
morning in heparinized tubes and analysed within 4 h. The
following lymphocyte subsets were analysed: CD19+ (B
cells), CD3 + (total T cells), CD4+ (T-helper cells) and CD8 +
(cytotoxic/suppressor T cells). On all T-cell subsets the fol-
lowing markers were measured: CD25, DR and CD54
(ICAM-1: intercellular adhesion molecule 1) which are
expressed on activated cells [20]; L-selectin (LAM-1: leuko-
cyte adhesion molecule 1) reported to be decreased during
activation [21]; CD45RA (naive T cells) and CD45RO
(memory T cells) [20]. All antibodies except CD45RO
(Serotec, Oxford, UK) and CD54 (Dako, Bucks, UK) were
purchased from Becton-Dickinson (BD), Oxford, UK.
Monoclonal antibodies labelled with either fluorescein isothi-
ocyanate (FITC) or phycoerythrin (PE) were added to the
heparinized whole blood. The cells were incubated with
antibody for 10 min at room temperature, then the red blood
cells were lysed with FACS Lysing Solution (BD). The cells
were washed twice and analysed immediately using a
FACScan flow cytometer. The lymphocyte population was
gated using forward and 90 ° angle light scatter. Cells staining
positive for FITC, PE or both were expressed as percentages
using FACScan Lysis II analysis program (BD).
Serum and urine soluble interleukin 2 receptor (sIL2R).
SIL2R was measured using an ELISA test kit (Cellfree, T
Cell Diagnostics, MA, USA). In addition sIL2R was ana-
lysed in 11 age-matched healthy controls attending the Dental
Clinic at our Hospital. The samples were stored at — 70 °C
until required. The assay was performed according to the kit
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manufacturer's instructions. In brief, a murine monoclonal
antibody to human IL2R was precoated onto polystyrene
microtitre wells. Standards and samples were added to the
wells followed by addition of a horseradish-peroxidase con-
jugated anti IL2R monoclonal antibody binding to a second
epitope. Unbound components were removed by washing.
O-phenylenediamine was added to the wells, the reaction
was terminated by addition of sulphuric acid and absorbance
read at 490 run. A standard curve was prepared from the
IL2R standards and unknown values determined from the
standard curve. The sensitivity of the assay was 24 U/ml.
Cholesterol and triglyceride concentrations (Kodak
Ektachem) were also measured.
Statistical methods. A paired t test was performed to
determine the significance of difference between the mean of
results in remission and the result in relapse; the results were
expressed as mean difference and 95% confidence interval.
An unpaired / test was used to analyse the difference in the
sIL2R data between patients and controls; the results were
expressed as mean ± SD.
Results
Fifteen patients relapsed during the study with a mean
urine albumin/creatinine ratio of 7.9 mg/mg. Their
median age was 11.5 years (range 6.6-17.0); 12 were
males and three females. At study entry they had been
off treatment for a median period of 2 weeks (range
2-48) and had a median of 3 (range 1-5) investigations
during remission. The last treatment had consisted of
cyclosporin A (8 children), steroids (5), and levami-
sole (2).
Lymphocyte subsets. There was no difference between
remission and relapse in CD3+ cells (68% versus 67.9),
CD4+ (35.8% versus 37.1), CD8+ (35.1% versus 34.4)
and CD19+ (17.3% versus 17.7). However, there was
a highly significant increase in the proportion of CD4+
cells expressing CD25 in relapse (Table la; Figures la
and lb). To test whether CD25 expression was gradu-
ally increased in remission prior to relapse, we also
compared the last investigation in remission with
relapse (median interval 2 weeks): There was also a
significant increase (Table lb). The sequential data of
eight patients (all had at least three investigations in
remission) are shown in Figures 2a and 2b. Comparing
the first with the last investigation in remission (median
interval 4 weeks), there was even a decrease:
%CD4+25+ 6.4 versus 5.4, and %CD25+ per CD4+
18.4 versus 14.0. However, there was again a significant
increase in relapse: %CD4+25+ 6.9, and %CD25+ per
CD4+ 18.9 (/><0.02 and <0.005 respectively).
In addition to CD25 we examined a range of other
T-cell markers. The subsets CD3+25+ (5.8 versus 7.3),
CD3+DR+ (4.6 versus 5.5), CD3+LAM1+ (36.7
versus 44.6), CD4+LAM1 + (20.8 versus 25.5) and
CD8+DR+ (2.8 versus 3.5) showed a small but statist-
ically significant (P<0.05) increase in relapse. All other
subsets did not differ between remission and relapse
(data not shown).
Soluble IL2 receptor. There was no difference in
serum between remission and relapse (713 + 505 U/ml
versus 710 + 409 U/ml). However, there was a signiric-
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Table la. Expression of CD4+25+ in remission (mean of all investigations) and relapse (« = 15)
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CD
marker
%4 + 25 +
%25+ per 4 +
4+25+ (109/l)
Mean of
remission
5.6
15.8
0.140
Mean of
relapse
7.0
19.1
0.167
Mean
difference
1.4
3.3
0.027
95% Confidence
interval
0.8-1.9
1.6-5.1
0.001-0.053
P
< 0.0005
< 0.001
<0.05
(% 4+25 + : % of total lymphocytes; % 25+ per 4+; % 25+ of total CD4+).
Table lb. Expression of CD4+25+ in remission (last investigation) and relapse (« = 15)
CD
marker
%4+25 +
% 25+ per 4 +
4+25+ (109/l)
Mean of
remission
5.5
14.9
0.130
Mean of
relapse
7.0
19.1
0.167
Mean
difference
1.5
4.2
0.037
95% Confidence
interval
0.8-2.2
2.0-6.4
0.001-0.073
P
< 0.0005
<0.001
<0.05
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Fig. la. Percentage of CD4+25+ lymphocytes. Mean of remission
versus relapse. Last treatment: cyclosporin A • (n = 8), steroids A
(n = 5), levamisole • (n = 2).
Fig. lb. Percentage of CD25+ per CD4+ lymphocytes. Mean of
remission versus relapse, (symbols, see Figure la).
11
10
9
8
7
6
5
4
3
2
1
0
(a)
30 -r
25
20
15
10
5
0
(b)
Remission Relapse
Remission Relapse
11
10
9
8
7
6
5
4
3
2
1
0
30
25
20
15
10
Fig. 2a. Percentage of CD4+25+ lymphocytes. Sequential data in
remission (3-5 investigations) and relapse (M = 8).
Fig. 2b. Percentage of CD25+ per CD4+ lymphocytes. Sequential
data in remission and relapse.
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Table 2. Soluble IL2 receptor (sIL2R) in urine {n= 15)
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Marker Mean of
remission
Mean of
relapse
Mean
difference
95% Confidence
interval
sIL2R U/mg
creatinine
sIL2R fracta
clearance (x 103)
272 (±308)
1.83
592 (±440)
5.22
320
3.39
91-549
0.58-6.20
<0.01
<0.05
(SD in parentheses). "Fractional clearance: [urine sIL2R (U/ml)x plasma creatinine (mg/ml)]: [serum sIL2R (U/ml)x urine creatinine
(mg/ml)].
ant increase in the urinary excretion (Table 2). There
was a positive correlation between the fractional clear-
ance of sIL2R and albumin (r = 0.56, P<0.05), but no
correlation between serum or urine sIL2R and
CD4+25+ cells. Serum and urine concentrations
of sIL2R did not differ between patients in remission
and controls (serum: 724 + 215 U/ml, urine:
360 + 372 U/mg creatinine).
Plasma lipids and albumin. These were also measured
as the changes in CD4+25+ might be secondary due
to the nephrotic state itself. Mean cholesterol concen-
tration (mmol/1) rose from 4.55 (normal range 3.1-5.4)
to 6.86 in relapse (P<0.05), triglycerides were
unchanged and mean albumin (g/1) dropped from 42
to 31 (P<0.005), though with only three patients
in the 'nephrotic range' of < 25 g/1. There were no
correlations between cholesterol or albumin and
CD4+25+ T cells.
Patients in sustained remission. Fourteen patients
remained in remission during the study and had five
investigations. There were no significant differences in
the lymphocyte results for this group compared with
the patients who subsequently relapsed: CD3+ 72.6%,
CD4+ 39%, CD8+ 34%, CD4+25+ 5.4%, and CD25 +
per CD4+ 14.2%). The sequential data for
%>CD4+25+ are shown in Figure 3 (mean of first and
last investigation: 5.6 and 5.4%> respectively). The
treatment before study entry differed only in cyclospo-
rin A (1/14 patients versus 8/15 of'relapsers'; P<0.05,
Fisher's exact test), but not in steroids, levamisole, or
cyclophosphamide (4, 7, and 2 patients, respectively).
Fig. 3. Percentage of CD4 + 25 + lymphocytes. Sequential data in
patients («=14) with sustained remission (five investigations).
Discussion
We performed a longitudinal study in SSNS to analyse
T-cell activation. The proportion of CD4+ cells
expressing the activation marker CD25 was increased
in early relapse compared both with the mean of
sequential investigations and with the last observation
in remission, immediately prior to relapse. These find-
ings indicate T-helper cell activation. The absolute
changes were not large, but—by performing a paired,
sequential study—the results were highly significant.
The absolute lymphocyte count is often unreliable, and
T-cell subset data is best expressed in percentages [22].
In remission, variability between patients was con-
sistently greater than within patients. Therefore signi-
ficant changes might be missed if different patients are
analysed in remission and relapse. Immunosuppressive
treatment reduces the number of circulating T lympho-
cytes, with T cells more affected than B cells; in vivo
studies with single-dose corticosteroids showed a tran-
sient effect lasting less than 24 h [18]. All patients had
been on long-term immunosuppression, but had been
off treatment for at least 2 weeks when investigated.
No significant adaptive changes in subsets (in particu-
lar no increase in the expression of CD25) were
observed during the sequential analysis in remission,
which took on average 4 weeks, suggesting that there
was no longer-lasting effect of the immunosuppression.
Yet we cannot rule out an increase immediately before
relapse as the last investigation in remission was (on
average) 2 weeks before relapse.
Are these statistical changes of clinical significance?
In SSNS, remission is induced and maintained by
immunosuppressive treatment. Steroids and cyclospo-
rin A inhibit the IL2/IL2R activation pathway [17,23].
Injection of supernatant from stimulated T lympho-
cytes [24] or T lymphocyte hybridomas [25] from
patients in relapse into rats induces transient pro-
teinuria and loss of the glomerular polyanion. These
clinical and experimental observations are consistent
with our findings and suggest that activated T lympho-
cytes are involved in the pathogenesis of SSNS.
This is the first study showing longitudinal data for
sIL2R in remission and subsequent relapse, both in
serum and urine. In contrast to previous studies,
including one from our unit, we could not confirm
increased serum concentrations of sIL2R [13,15]. All
our patients were in early relapse and highly nephrotic,
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demonstrating a significant urinary loss of sIL2R. This
makes the interpretation of serum sIL2R inconclusive.
Urinary sIL2R excretion was positively correlated with
albumin excretion. SIL2R is smaller than albumin
(molecular weight 35-46 kDa versus 66), but has
almost the same pi (5.05 versus 4.9) [14]. Although
the tubular handling of sIL2R is unknown, the urinary
loss could be due to enhanced glomerular filtration.
No correlation was found between serum sIL2R con-
centration and the proportion of activated T helper
cells (CD4+25+).
It has been suggested that some of the T cell altera-
tions in SSNS are epiphenomena of the nephrotic state.
Lipoproteins possess immunomodulatory properties in
vitro: At lower concentrations they induce T-cell activa-
tion with increased CD25 and DR expression [26], at
higher concentrations they suppress mitogenesis [27].
The latter may explain (at least in part) the decreased
blastogenic response in SSNS [2,3]. In relapse the
plasma cholesterol was significantly raised, but only
three patients had a plasma albumin in the nephrotic
range; there were no correlations between albumin or
cholesterol and CD4+25+ cells. It is therefore unlikely
that the T-cell activation is caused by changes in
albumin or lipids.
CD3 + , CD4+ and CD8+ subsets were similar in
remission and relapse and were within the range of
age-related controls [16]. The observed increases in
CD3+25 +, CD3+DR+, and CD8+DR + cells in relapse
are consistent with T cell activation, but these data
need further confirmation. We analysed 22 lymphocyte
subsets; this implies, apart from the primary hypo-
thesis, a 0.68 probability (1-0.9522) of getting at least
one spuriously significant result at the 5% level. In
contrast to previous in-vitro data [21], but consistent
with clinical data in SSNS [10], we found a rise in
CD3+LAM1 + and CD4+LAM1 + during T-cell activa-
tion in relapse.
We conclude that relapse of SSNS is associated with
activation of CD4+ (T-helper) cells, expressing CD25.
Our results suggest that this activation is not secondary
due to the nephrotic state itself. However, the precise
role of activated T-helper cells in the pathogenesis of
SSNS is still unclear.
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